Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Exclusive Article from MarketBeat.com
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?By Jeffrey Neal Johnson. Date Posted: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking.
Millionaire Trader Exposes: "The Single Stock Income Plan"
With over 6,000 stocks on the market to choose from...
Millionaire trader Nate Bear IGNORES 99% of them...
Instead, he trades just one...
He calls it: "The Single Stock Income Plan".
And in a single month, while the S&P 500 handed investors a measly 0.05% return...
His readers had the chance to collect: 100% in the same day... 100% overnight... 100% in 3 days... and 114% in 3 days.
Four separate trades. One stock. And all could've DOUBLED your money.
That's the equivalent of collecting 40 YEARS of typical stock market gains... crammed into a single month. Click here for details
Abbott Laboratories’ stock price recently touched its 52-week low, closing just above $100 in late March. This sharp downturn has left many wondering whether the foundation of this industry leader is cracking. A closer look at Abbott Laboratories’ situation suggests a potential disconnect between market sentiment and operational reality. The key question for investors is whether the market's pessimism is justified, or if a meaningful value opportunity has emerged for those with a long-term horizon. Separating the Signal From the NoiseStocks rarely decline without reason. Abbott’s recent drop reflects two distinct pressures. The first is an internal headwind in its Nutrition segment. Abbott’s fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in this division, driven mainly by market-share losses in the U.S. pediatric business and pricing dynamics that constrained volume. Management has been transparent about the issue and laid out a clear turnaround plan. CEO Robert B. Ford described pricing and promotional initiatives and a pipeline of at least eight new product launches in 2026 aimed at reigniting volume, with a return to growth expected in the second half of the year. The second factor is external and broader in scope: a widespread rotation of capital across the market. In periods of economic optimism, investors often reallocate funds away from defensive sectors like the healthcare sector into higher-beta areas such as artificial intelligence (AI) and the energy sector in pursuit of faster returns. That macro trend has pressured many fundamentally sound healthcare companies, including Abbott, for reasons largely unrelated to their individual performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile the Nutrition segment works through a short-term recovery, Abbott’s core businesses remain solid—led by its largest and most profitable division, Medical Devices. That segment is accelerating, posting 10.4% organic growth in the most recent quarter. Abbott’s diversified model provides a strong counterbalance to the isolated weakness in Nutrition; the company’s true health is most evident in these high-performing areas.
Medical Devices: The Medical Devices business is firing on multiple cylinders, driven by market-leading innovation in critical care areas. Diabetes Care: The FreeStyle Libre family of continuous glucose monitors (CGM) remains a growth engine. This product line, which lets users track glucose levels without routine fingersticks, generated more than $7.5 billion in sales in 2025 and is a primary driver of Abbott’s sustained success. Cardiovascular Leadership: Abbott is a major force in cardiovascular care. Its Electrophysiology business grew at a double-digit pace, while Structural Heart posted strong organic growth of 8.7%. This performance is supported by best-in-class products like MitraClip and TriClip for minimally invasive valve repair, along with a pipeline of innovations including the recently FDA-approved Volt PFA System for treating atrial fibrillation. Abbott is also taking strategic steps to secure future growth through its acquisition of Exact Sciences. Exact Sciences is a leader in cancer screening and diagnostics, best known for the non-invasive colon cancer test Cologuard. The deal would immediately position Abbott in the rapidly expanding, multi-billion-dollar market for cancer diagnostics, adding a high-growth vertical that could become a significant revenue contributor for years to come. This bullish view is echoed by Wall Street, which maintains a Moderate Buy consensus rating on the stock. The average 12-month price target is $135.47, implying potential upside of more than 30% from current levels and suggesting many analysts see the shares as undervalued. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on income, Abbott’s dividend is a compelling reason to consider the stock. Abbott is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have increased their dividend for at least 50 consecutive years. That track record demonstrates a deep commitment to returning capital to shareholders through varying market cycles. The recent decline in Abbott’s stock price has a direct benefit for new investors: a higher dividend yield. At current levels, Abbott yields about 2.5%, allowing investors to lock in a higher income rate from a historically reliable payer. The dividend also appears secure—the payout ratio is roughly 68% of earnings, and the dividend represents only about 37% of cash flow, indicating Abbott generates ample cash to cover distributions with room for future increases. A Disconnect Between Price and ValueCurrent market sentiment around Abbott appears misaligned with the company’s operational strength. Temporary headwinds in a single division, combined with a broader market rotation, have weighed on the stock price. Meanwhile, Abbott’s core growth engines are accelerating, its dividend remains a dependable income source, and strategic catalysts such as the Exact Sciences acquisition could drive future upside. For investors with a long-term perspective, the present valuation highlights a meaningful gap between price and underlying value that deserves serious consideration. |
